Spots Global Cancer Trial Database for macular edema
Every month we try and update this database with for macular edema cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | NCT00056199 | Hippel-Lindau D... | EYE001 | - | National Institutes of Health Clinical Center (CC) | |
| Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety | NCT02953938 | Macular Edema S... | Ranibizumab Grid&Direct sho... | 20 Years - | Novartis | |
| Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | NCT00089765 | Von Hippel-Lind... | Ranibizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) | NCT01976338 | Macular Edema S... | Ranibizumab 0.5... Sham injection | 18 Years - | Novartis | |
| An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2) | NCT01442064 | Macular Edema Retinal Vein Oc... | Ranibizumab 0.5... | 18 Years - | Genentech, Inc. | |
| An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2) | NCT01442064 | Macular Edema Retinal Vein Oc... | Ranibizumab 0.5... | 18 Years - | Genentech, Inc. | |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) | NCT01976338 | Macular Edema S... | Ranibizumab 0.5... Sham injection | 18 Years - | Novartis | |
| Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety | NCT02953938 | Macular Edema S... | Ranibizumab Grid&Direct sho... | 20 Years - | Novartis | |
| Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | NCT01471054 | Macular Edema Cystoid Macular... Uveal Melanoma Radiation Macul... Radiation Retin... | Ozurdex Bevacizumab | 18 Years - | Wills Eye | |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) | NCT01976338 | Macular Edema S... | Ranibizumab 0.5... Sham injection | 18 Years - | Novartis | |
| A Post-Authorization, Long-term Study of Ozanimod Real-world Safety | NCT05605782 | Multiple Sclero... | 18 Years - | Bristol-Myers Squibb | ||
| Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety | NCT02953938 | Macular Edema S... | Ranibizumab Grid&Direct sho... | 20 Years - | Novartis | |
| Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) | NCT00943072 | Macular Edema S... | VEGF Trap-Eye 2... Sham | 18 Years - | Regeneron Pharmaceuticals | |
| Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) | NCT00943072 | Macular Edema S... | VEGF Trap-Eye 2... Sham | 18 Years - | Regeneron Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
